COMING SOON Clinical Trials
In-vivo study of KSP/QRH heptapeptide dimer for detection of biliary intra-epithelial neoplasia
This study is testing a new experimental drug to learn about feasibility for use in early detection of diseases of the bile duct or bile duct cancer. The drug will be sprayed onto the tissue lining of the subject’s bile duct during their ERCP. Researchers want to understand how the drug works in the subject’s body and how they will react to it. This study will help the researchers to develop new technologies for improved detection of biliary disease.
PI: Templeton
Site: UWMC - DHC
The primary purpose of this study is to evaluate the safety and efficacy of larsucosterol, as determined by transplant-free survival through Day 90 in participants with severe alcohol-associated hepatitis (AH) with pre-treatment Maddrey Discriminant Function (MDF) score greater than or equal to (>=) 32 and Model for End-stage Liver Disease (MELD) scores 21-30, inclusive.
Site: HMC
This is a multicenter evaluation of seladelpar, administered as a once daily oral capsule, in a randomized, double-blind, placebo-controlled, parallel-group study in subjects with PBC. This fixed-duration study (156 weeks) will randomize approximately 318 subjects across approximately 250 sites worldwide. The population to be studied is patients with PBC and compensated cirrhosis restricted to Child-Pugh (CP)-A or CP-B.
Site: UWMC
Gilead GS-US-763-7930 (FORTIFY): A Phase 2 Proof-of-Concept Study with a Randomized, Double-Blind, Placebo-Controlled Period, Followed by an Active Treatment Extension Period to Assess the Safety and Efficacy of Seladelpar and Cilofexor in Combination for Primary Biliary Cholangitis
Site: UWMC
This study is to evaluate the safety and efficacy of 2 different dose levels of ANG003 compared to commercially available Creon in subjects with EPI due to cystic fibrosis (CF), to inform future development. The Off-Enzyme arm is intended to provide additional exploratory baseline comparison to assess EPI disease severity as has been done historically to evaluate enzymes currently on the market and inform future development. Subjects with an on-enzyme baseline CFA of 60 to <80% have not been previously well studied; therefore, allowing these subjects to enroll will help to inform and understand subject baseline characteristics and potential treatment comparison with CFA ≥80% and inform future development.
PI: Derleth
Site: UWMC
Multi-Hole IDE Clinical Trial
The objective of this study is to demonstrate clinical safety and performance of the HANAROSTENT® Multi-Hole™ Biliary Stent for the palliative treatment of malignant biliary obstruction.
PI: Templeton
Site: UWMC - DHC